Entero Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q3 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Entero Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2015 to Q3 2024.
  • Entero Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$1.89M, a 44.9% increase year-over-year.
  • Entero Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$18.6M, a 33.5% decline year-over-year.
  • Entero Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$15.8M, a 24.4% decline from 2022.
  • Entero Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$12.7M, a 78.5% increase from 2021.
  • Entero Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$59.1M, a 123% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$18.6M -$1.89M +$1.54M +44.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$20.2M -$3.43M +$756K +18.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-10-21
Q1 2024 -$20.9M -$9.23M -$5.16M -127% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$15.8M -$4.09M -$1.81M -79.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 -$14M -$3.43M -$7.82M -178% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$6.13M -$4.18M +$1.22M +22.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-21
Q1 2023 -$7.36M -$4.06M +$5.32M +56.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$12.7M -$2.28M +$8.89M +79.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 -$21.6M $4.39M +$34.8M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$56.4M -$5.41M +$3.87M +41.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$60.2M -$9.38M -$1.17M -14.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$59.1M -$11.2M +$6.23M +35.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-20
Q3 2021 -$65.3M -$30.4M -$26.7M -719% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$38.6M -$9.28M -$6.88M -288% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$31.7M -$8.21M -$5.29M -180% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-23
Q4 2020 -$26.4M -$17.4M -$16.3M -1445% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$10.2M -$3.71M +$370K +9.07% Jul 1, 2020 Sep 30, 2020 10-Q/A 2021-11-16
Q2 2020 -$10.5M -$2.39M +$2.54M +51.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$13.1M -$2.93M +$1.68M +36.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-24
Q4 2019 -$14.7M -$1.13M +$2.89M +72% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$17.6M -$4.08M -$1.52M -59.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$16.1M -$4.93M -$1.67M -51.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$14.5M -$4.6M -$1.02M -28.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$13.4M -$4.02M -$1.72M -74.6% Oct 1, 2018 Dec 31, 2018 10-K 2019-04-01
Q3 2018 -$11.7M -$2.57M +$160K +5.87% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$11.9M -$3.26M -$879K -36.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 -$11M -$3.58M -$776K -27.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 -$10.2M -$2.3M -$1.24M -116% Oct 1, 2017 Dec 31, 2017 10-K 2019-04-01
Q3 2017 -$8.98M -$2.73M -$538K -24.6% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$8.45M -$2.38M -$659K -38.2% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 -$7.79M -$2.81M -$1.46M -108% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$6.33M -$1.06M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-16
Q3 2016 -$2.19M -$779K -55.3% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$1.72M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$1.35M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q3 2015 -$1.41M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.